Retracted: Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566.

Abstract

Retraction: "Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566" by R. M. J. Deacon, M. J. Hurley, C. M. Rebolledo, M. Snape, F. J. Altimiras, L. Farías, M. Pino, R. Biekofsky, L. Glass and P. Cogram. The above article, from Genes, Brain and Behavior, published online on 12th May 2017 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor in Chief, Andrew Holmes and John Wiley & Sons Ltd. The retraction has been agreed as all authors cannot agree on a revised author order, and at least one author continues to dispute the original order. In this case, the original article is being retracted on the grounds that the journal does not have permission to publish. Reference: Deacon, R. M. J., Hurley, M. J., Rebolledo, C. M., Snape, M., Altimiras, F. J., Farías, L., Pino, M., Biekofsky, R., Glass, L. and Cogram, P. (2017), Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566. Genes, Brain and Behavior. doi:10.1111/gbb.12373.

DOI: 10.1111/gbb.12373
Showing 1-10 of 32 references

Factor Erythroid 2-Related Factor 2 Activation

  • H. Yamazaki, K. Tanji, K. Wakabayashi, S. Matsuura, K. Itoh
  • 2015
1 Excerpt

The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo

  • J. Panee
  • 2014
1 Excerpt

Parkinson’s Disease Models

  • H. Motohashi, M. Yamamoto
  • 2013

markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome

  • E. Berry-Kravis, D. Hessl, L. Abbeduto, A. L. Reiss, A. Beckel-Mitchener, T. K. Urv
  • 2013